CRISPR Therapeutics unites with ViaCyte to treat diabetes

19-09-2018

CRISPR Therapeutics unites with ViaCyte to treat diabetes

filograph / iStockphoto.com

Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.


ViaCyte, CRISPR, CRISPR Therapeutics, commercialisation, licence, gene editing, CRISPR/Cas9, regenerative medicine, stem cell therapies

LSIPR